Basit öğe kaydını göster

dc.contributor.authorAYDIN, Kadriye
dc.contributor.authorERSÖZ GÜLÇELİK, Neşe
dc.contributor.authorTUNCEL, Murat
dc.contributor.authorBALCI, Cafer
dc.contributor.authorAKIN, Şafak
dc.contributor.authorÇINAR, Neşe
dc.contributor.authorFIRAT, Firuzan
dc.contributor.authorÇAĞLAR, Meltem
dc.contributor.authorUSMAN, Aydan
dc.contributor.authorGÜRLEK, Alper
dc.date.accessioned2021-06-03T05:42:55Z
dc.date.available2021-06-03T05:42:55Z
dc.date.issued2019
dc.identifier.issn1300-0144
dc.identifier.urihttp://dx.doi.org/10.3906/sag-1708-106
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018346/
dc.identifier.urihttp://hdl.handle.net/11655/24103
dc.description.abstractBackground/aim Defective vascularization may be important in thyroid nodular disease. In this study, we aimed to investigate serum vascular endothelial growth factor (VEGF) levels in dyslipidemic patients with thyroid nodules, as well as the effects of statin therapy. Materials and methods The study included 37 dyslipidemic patients with thyroid nodules and 32 dyslipidemic patients without thyroid nodules. Anthropometry, serum VEGF levels, biochemical parameters, thyroid-stimulating hormone (TSH), free triiodothyronine (fT3) and free thyroxine (fT4) levels, and thyroid sonography were determined before and after 6 months of statin therapy. Results Patients with and without thyroid nodules had similar metabolic parameters. Serum VEGF levels did not differ between the groups. In patients with nodules, VEGF levels remained unchanged (P = 0.931) after statin therapy. However, serum VEGF levels were lowered by statin treatment in patients without nodules (P = 0.030). Statin therapy resulted in a decrease in the dominant thyroid nodule volume. The changes in thyroid volume and dominant thyroid nodule volume were not correlated with changes in VEGF, body mass index, total cholesterol, low-density lipoprotein cholesterol, or homeostatic model assessment of insulin resistance (HOMA-IR). Conclusion Although statin treatment decreases serum VEGF levels in dyslipidemic patients without thyroid nodules, it has no lowering effect on serum VEGF levels in patients with thyroid nodules. The decrease in thyroid nodule volume with statin treatment was associated with neither metabolic parameters nor serum VEGF levels.
dc.language.isoen
dc.relation.isversionof10.3906/sag-1708-106
dc.rightsAttribution 4.0 United States
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleThyroid Volumes And Serum Vegf Levels In Dyslipidemic Patients: Effects Of Statin Treatment
dc.title.alternativeThyroid volumes and serum VEGF levels in dyslipidemic patients
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalTurkish Journal Of Medical Sciences
dc.contributor.departmentNükleer Tıp
dc.identifier.volume49
dc.identifier.issue3
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

Attribution 4.0 United States
Aksi belirtilmediği sürece bu öğenin lisansı: Attribution 4.0 United States